"Financial support of social solidarity, social responsibility contribution of large enterprises and of large real estate and other provisions of the Ministries of Finance, Labour and Social Security, Health and Social Solidarity" - Draft Law
Project of royal decree modifying article 75 of the royal decree of 20 July 2001 concerning the general regulation for the protection of the population, the workers and the environment against the danger of ionising radiations - opinion 1710
Project of ministerial decree determining the daily estimated income for the calculation of the social security contributions of the toilet attendants whose income consists entirely or partly of tips or service charges and of their employers who do not...
Project of ministerial decree determining the daily estimated income for the calculation of the social security contributions of the toilet attendants whose income consists entirely or partly of tips or service charges and of their employers who do not come under the joint committee for the hotel industry - opinion 1709
OPINION 4/2009 on the draft Ministerial Order that would determine new sets of medicinal products, their reference prices, and a review of the reference prices determined in Order SCO/3803/2008 of 23 December 2008
The ESC has a positive opinion on the system of reference prices, considering it a suitable way of contributing to the rationalisation of public expenditure on medicinal products, The Council qualifies its assessment by indicating that these initiatives are positive provided that they are part of a coherent set of measures integrated into a framework of policies aimed at the rational use of medicaments. In this respect, it notes that the system of reference prices has made an efficient contribution to containing the growth of pharmaceutical expenditure.The report points out that pharmaceutical expenditure is currently more affected by an increase in the number of prescriptions than by the average cost per prescription. Based on data from the Ministry of Health and Social Policy for July 2009, it points out that year-on-year growth of public pharmaceutical expenditure in Spain stands at 4.68pc; this is a consequence of an increase in the number of prescriptions of 4.31pc and an increase in the average cost per prescription of 0.36pc.The ESC warns that, while defending measures to rationalise pharmaceutical expenditure, this should not be to the detriment of citizens rights to health and quality provision of pharmaceutical products.
